Azole interactions with multidrug therapy in pediatric oncology.
Patients with cancer receive multidrug therapy. Antineoplastic agents and supportive care drugs are often administered together, leading to potential drug-drug interactions. These interactions may have significant clinical implications in terms of toxicity or a decrease in the efficacy of the treatment administered. Here, we focus on the role of azoles and their main pharmacokinetic interactions with the principal classes of drugs used in pediatric oncology. The co-administration of azoles and antineoplastic agents, corticosteroids, immunosuppressants, antacids, antiemetics, antiepileptic drugs and analgesics was investigated, and a practical guide on the management of these drugs when administered together is provided.
Pediatric Oncology Division, "A. Gemelli" Hospital, Catholic University of Rome, Largo A. Gemelli, 00168 Rome, Italy. ruggiero@rm.unicatt.it
Antonio
A
Ruggiero
Roberta
R
Arena
Andrea
A
Battista
Daniela
D
Rizzo
Giorgio
G
Attinà
Riccardo
R
Riccardi
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000863:Antacids / Q000008:administration & dosage; D000927:Anticonvulsants / Q000008:administration & dosage; D000932:Antiemetics / Q000008:administration & dosage; D000935:Antifungal Agents / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001393:Azoles / Q000008:administration & dosage*; D002648:Child; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy*
D000305:Adrenal Cortex Hormones; D000863:Antacids; D000927:Anticonvulsants; D000932:Antiemetics; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D001393:Azoles; D007166:Immunosuppressive Agents